This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.80% per year. These returns cover a period from January 1, 1988 through August 3, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
Acadia's Daybue Patent Allowance Extends U.S. Protection to March 2041
by Zacks Equity Research
ACAD gains a potential patent extension for Daybue to 2041, while strong sales growth and EU approval expand trofinetide's reach.
ACADNegative Net Change ALDXNegative Net Change ACIUPositive Net Change PGENPositive Net Change
biotechnology biotechs medical pharmaceuticals
Merck, Daiichi Withdraw FDA Filing for Lung Cancer Therapy
by Zacks Equity Research
MRK and Daiichi withdraw an FDA filing for ifinatamab deruxtecan after data falls short, while late-stage studies continue.
MRKNegative Net Change GSKNegative Net Change RHHBYNegative Net Change
biotechs medical pharmaceuticals
FDA Expands Merck's Welireg Label for a New Kidney Cancer Indication
by Zacks Equity Research
FDA expands MRK's Welireg label for advanced kidney cancer, adding a third indication as sales climb and the drug gains wider use.
MRKNegative Net Change ACIUPositive Net Change PGENPositive Net Change
biotechs medical pharmaceuticals
Implied Volatility Surging for ANI Pharmaceuticals Stock Options
by Zacks Equity Research
Investors need to pay close attention to ANIP stock based on the movements in the options market lately.
ANIPPositive Net Change
biotechs medical pharmaceuticals
LLY's Olumiant Gets FDA Nod for Expanded Use in Pediatric Hair Loss
by Zacks Equity Research
Eli Lilly's Olumiant wins FDA nod to treat pediatric patients 12 years of age and older with severe alopecia areata, expanding its U.S. use after strong phase III results.
LLYNegative Net Change INCYNegative Net Change ACIUPositive Net Change PGENPositive Net Change
biotechnology biotechs medical pharmaceuticals
4 RNA Therapeutics Stocks Leading the Next Wave of Innovation
by Ahan Chakraborty
RNA therapeutics are gaining momentum as Alnylam, Ionis, Wave Life Sciences and Arcturus advance innovative treatments targeting a range of diseases.
ALNYNegative Net Change ARCTNegative Net Change IONSNegative Net Change WVEPositive Net Change
biotechnology biotechs medical pharmaceuticals
Can Biogen's Growth Portfolio Maintain Its Lead Over Legacy MS Drugs?
by Kinjel Shah
BIIB's growth products now outpace its legacy MS portfolio, with Skyclarys, Zurzuvae and newer drugs driving a shift in revenue mix.
BIIBNegative Net Change LLYNegative Net Change SUPNNegative Net Change ABBVNegative Net Change
biotechs
ACAD Stock Down 13% as Phase II Alzheimer's Study Misses Primary Goal
by Zacks Equity Research
Acadia stock falls 13% after its Alzheimer's psychosis study narrowly misses its primary goal, though 60 mg results support continued phase III development.
ACADNegative Net Change ALDXNegative Net Change ACIUPositive Net Change PGENPositive Net Change
biotechnology biotechs medical pharmaceuticals
Can Recent Traction With Key Drugs and Pipeline Progress Boost BMY?
by Ekta Bagri
Bristol Myers Squibbs' growth portfolio is gaining ground, with newer drugs offsetting mature-product declines and reshaping its revenue mix.
BMYNegative Net Change PFENegative Net Change MRKNegative Net Change
biotechnology biotechs medical pharmaceuticals
Could Zanzalintinib's FDA Delay Affect Exelixis' Growth Plans?
by Zacks Equity Research
Exelixis faces a three-month FDA review delay for zanzalintinib, pushing the potential CRC decision to March 2027.
EXELNegative Net Change RHHBYNegative Net Change MRKNegative Net Change
biotechnology biotechs medical pharmaceuticals